Stockreport

Amgen ends collaboration agreement with Kyowa Kirin for eczema asset [Seeking Alpha]

KIRIN HLDGS CO LTD S/ADR  (KNBWY) 
US:NASDAQ Investor Relations: kirinholdings.co.jp/english/ir
PDF pharma Kyowa Kirin ( KYKOF ) regarding the development of the biologic roctinlimab for atopic dermatitis. In 2021, Amgen paid $400M for the rights to co-develop and co [Read more]